Article Text

other Versions

Relationship of QRS duration at baseline and changes over 60 minutes after fibrinolysis to 30-day mortality with different locations of ST elevation myocardial infarction: Results from the HERO-2 trial
  1. Cheuk-Kit Wong (cheuk-kit.wong{at}
  1. Dunedin School of Medicine, University of Otago, New Zealand
    1. Wanzhen Gao (wanzhen.gao{at}
    1. Akoranga Campus, Auckland University of Technology, New Zealand
      1. Ralph A H Stewart (rstewart{at}
      1. Auckland City Hospital; Green Lane Cardiovascular Services, New Zealand
        1. John K French (j.french{at}
        1. Department of Cardiology, Liverpool Hospital, Sydney, Australia
          1. Philip E G Aylward (p.aylward{at}
          1. Flinders Medical Centre, Flinders Drive, Australia
            1. Harvey D White (harveyw{at}
            1. Auckland City Hospital; Green Lane Cardiovascular Services, New Zealand


              Objective: To discern if the prognostic meaning of QRS prolongation differs according to the location of ST elevation acute myocardial infarction.

              Design: Measuring QRS duration in patients with normal conduction or right bundle branch block.

              Setting: HERO-2 trial with prospective collection of electrocardiograms at randomization and at 60 minutes after fibrinolytic therapy.

              Patients: 12,456 patients with normal conduction at both randomization and 60-minutes time points and 510 with RBBB at both time points.

              Main outcome measure: 30-days mortality.

              Results: On the baseline ECG, there was a positive association between QRS duration and 30-day mortality with anterior AMI (P<0.0001 for those with normal conduction and =0.007 for those with RBBB) but not with inferior AMI (P=0.29 and P=0.32 respectively). For anterior AMI, with or without RBBB, an increment of 20 msec increase in QRS duration predicted a significant 30%-40% relative increase in 30-day mortality both before and after adjusting for clinical and ECG variables including baseline ST elevation and presence of Q wave. The association was not present for inferior AMI. Changes in QRS duration over 60 minutes after fibrinolytic therapy were uncommon and unrelated to mortality.

              Conclusion: Baseline QRS duration independently stratifies 30-day mortality in patients with anterior AMI even when unaccompanied by RBBB, but does not stratify mortality risk in patients with inferior AMI.

              Statistics from

              Request Permissions

              If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

              Linked Articles